title: Pretargeted radioimmunotherapy of human colorectal xenografts with bispecific antibody and 131I-labeled bivalent hapten.
abstract: We have developed a pretargeting strategy, called the affinity enhancement system (AES), which uses bispecific antibodies to target radiolabeled bivalent haptens to tumor cells. The aim of this study was to evaluate the potential of the AES for the radioimmunotherapy (RIT) of LS174T colorectal xenografts in comparison with RIT with directly labeled F(ab')2 fragment.
  
  
  METHODS
  A total of 6 groups of tumor-bearing mice were treated using anticarcinoembryonic antigen (CEA) x anti-diethylenetriamine pentaacetic acid (DTPA)-In bispecific antibody (BsF(ab')2) and 131I-labeled di-DTPA-In bivalent hapten. Three groups of mice were injected with various activities of 131I-labeled bivalent hapten (75, 96, and 112 MBq) 20 h after administration of BsF(ab)'2. Three other groups were injected with an almost constant activity of labeled hapten (102 MBq) at 3 time periods (15, 30, and 48 h) after BsF(ab')2 administration. For conventional RIT, mice were treated with 96 MBq 131-labeled anti-CEA F(ab')2. Control groups were left untreated. Toxicity and tumor growth were monitored at weekly intervals.
  
  
  RESULTS
  Doses used for conventional RIT induced severe toxicity and resulted in death of several treated animals. Nevertheless, all surviving animals treated with 131I-labeled anti-CEA F(ab')2 relapsed shortly after treatment (tumor growth delay = 48+/-13 d). For animals treated with the AES reagents, toxicity varied with the pretargeting time interval and the administered activity. For 20-h pretargeting time, the maximum tolerated dose was 96 MBq. For all AES RIT except 1 (with 48-h pretargeting time interval and growth delay of 82+/-26 d), no tumor growth was observed over a period of 8 mo. Furthermore, based on clinical and histologic criteria, 33% of the treated mice were considered cured.
  
  
  CONCLUSIONS
  High cure rates of LS174T colon carcinoma were achieved with the AES, and the flexibility of the pretargeting approach allowed the control of hematologic toxicity, which is the main limitation to dose escalation with conventional RIT.
authors.affiliation: Immunotech SA, Marseille, France.
authors.forename: E
authors.initials: E
authors.lastname: Gautherot
authors.forename: E
authors.initials: E
authors.lastname: Rouvier
authors.forename: L
authors.initials: L
authors.lastname: Daniel
authors.forename: E
authors.initials: E
authors.lastname: Loucif
authors.forename: J
authors.initials: J
authors.lastname: Bouhou
authors.forename: C
authors.initials: C
authors.lastname: Manetti
authors.forename: M
authors.initials: M
authors.lastname: Martin
authors.forename: J M
authors.initials: JM
authors.lastname: Le Doussal
authors.forename: J
authors.initials: J
authors.lastname: Barbet
mesh_terms: D000818:Animals; D018033:Antibodies, Bispecific; D015179:Colorectal Neoplasms / Q000532:radiotherapy*; D005260:Female; D006241:Haptens / Q000627:therapeutic use*; D006801:Humans; D007457:Iodine Radioisotopes / Q000627:therapeutic use*; D051379:Mice; D008819:Mice, Nude; D009368:Neoplasm Transplantation; D016499:Radioimmunotherapy; D014183:Transplantation, Heterologous
chemical_list: D018033:Antibodies, Bispecific; D006241:Haptens; D007457:Iodine Radioisotopes